Financial Results
Fresenius Q2/25: Guidance raised - Resilient business continues to deliver consistent performance
Q2/2025: Ongoing strong revenue and EPS growth, guidance for organic revenue growth raised
- Group revenue1 at €5,571 million with organic growth of 5%1,2 driven by consistent delivery across the core businesses Fresenius Kabi and Fresenius Helios as well as ongoing execution of #FutureFresenius.
- Group EBIT1 broadly stable3 in constant currency at €654 million impacted by the headwinds from ceased energy relief payments at Helios Germany and the loss of the volume-based procurement tender for the nutrition product Ketosteril in China at Fresenius Kabi; Group EBIT margin1 at 11.7%.
- Net income1,4 with strong 8%3 growth in constant currency to €412 million outpacing revenue growth.
- EPS1,4 rose by strong 8%3 in constant currency to €0.73 demonstrating continued bottom-line delivery based on operating strength and significantly decreased interest expenses.
- Net debt/EBITDA ratio at 3.1x1,5 driven by resumed dividend payment in Q2/25.
- Pro rata sale of Fresenius Medical Care shares to maintain current stake in response to the announced Fresenius Medical Care share buyback program.
1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation>
3 Growth rate adjusted for Argentina hyperinflation
4 Excluding Fresenius Medical Care
5 At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend, net debt adjusted for the valuation effect of the equity-neutral exchangeable bond
Selected Key Figures Q2/2025
GROUP REVENUE 1
€ 5571 m
+ 5% 2
Q2/24: €5,414 m
GROUP EBIT 1
€ 654 m
+0% 3
Q2/24: €660 m
NET INCOME 1, 4
€ 412 m
+8% 3
Q2/24: €388 m
EPS 1, 4
€ 0.73
+8% 3
Q2/24: €0.69
1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
3 Growth rate at constant currency (cc) and adjusted for Argentina hyperinflation
4 Excluding Fresenius Medical Care
Revenue by business segment
| € in millions | Q2/25 | Q2/24 | Growth at actual rates | Growth at constant rates | Organic growth1 | Acquisitions/Divestitures | % of total revenue |
|---|---|---|---|---|---|---|---|
Fresenius Kabi | 2,111 | 2,101 | 0% | 5% | 6%1 | -1% | 38% |
Fresenius Helios | 3,370 | 3,230 | 4% | 5% | 5% | 0% | 60% |
Total | 5,571 | 5,414 | 3% | 5% | 5% | 0% | 100%2 |
-
1 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
2 Remaining 2% Corporate/Other revenue
Before special items